"Dawada mucjisada ah ee miisaanka dhimista" waxay ku dhowdahay inay gasho Shiinaha!Novo Nordisk Shiinaha ayaa xaqiijinaysa nooca miisaanka dhimista ee Semaglutide in la ansixin doono sanadkan

"Dawada mucjisada miisaanka dhimista" waxay ku dhowdahay inay gasho Shiinaha!Novo Nordisk Shiinaha ayaa xaqiijinaysa nooca miisaanka dhimista ee Semaglutide in la ansixin doono sanadkan
March 8, news in Novo Nordisk ayaa la filayaa in version miisaanka oo yaraada ee Semaglutide Wegovy la ansixin doonaa Shiinaha sanadkan, wax soo saarka ayaa noqon doona bilowga bukaanada is-maalgeliyay, oo waxaa jira xad tirada bukaanada.Marka la eego, Novo Nordisk Shiinaha ayaa u xaqiijisay warka kor ku xusan weriyaha wararka ee kor u kacaya, "waxay rajaynaysaa in la ansixiyo sanadkan, sida ugu dhakhsaha badan ee suurtogalka ah si ay uga faa'iideysato bukaannada buuran ee Shiinaha."

Wegovy waa magaca ganacsiga Ingiriisiga ee GLP-1 daroogada Semaglutide ee ay samaysay Novo Nordisk ee calaamadaha dhimista miisaanka, kaas oo loo oggolaaday sidii daawo miisaan lumis bishii Juun 2021 gudaha Mareykanka.Maamulaha guud ee Tesla Musk ayaa mar uu baraha bulshada ku sheegay in uu dawadan u isticmaalay miisaan dhimis, waxaana mar loo raadiyay “daroogo mucjiso ah oo miisaan lumis”.

Shiinaha, cirbadeynta Semaglutide iyo daawada afka ayaa kaliya loo oggolaaday calaamadaha sonkorowga, kuwaas oo duritaanka simethicone loo oggolaan doono suuqgeynta Shiinaha Abriil 2021, ka dibna geli buugga caymiska caafimaadka qaranka ee 2022;Semaglutide afka laga qaato ayaa la ansixiyay bishii Jannaayo ee sanadkan, waxayna noqotay daawadii ugu horreysay ee GLP-1 afka laga qaato ee loo oggolaaday suuqgeynta Shiinaha.

Sida wakiilka dawooyinka GLP-1, Semaglutide waxay ku guulaysatay ganacsi ahaan.Warbixinta maaliyadeed ee Novo Nordisk ee 2023 ayaa muujisay in iibka Wegovy uu kor u kacay 406% ilaa $4.6 bilyan, taasoo hogaaminaysa jidka caalamiga ah ee GLP-1.Sidoo kale sababtan awgeed, shirkado badan oo dawooyinka gudaha ah ayaa qaabeynta Semaglutide biosimilar daroogada horumarinta, laakiin intooda badani waxay ku jiraan marxaladda hore ee bukaan-socodka, sida Liju Group (000513), Han Yu Pharmaceutical (300199) iyo shirkado kale oo badan oo dawooyin ah ayaa horay u shaaciyay in shirkadda Semaglutide. cirbadeynta ayaa la ansixiyay si loo sameeyo tijaabooyinka bukaan-socodka ee calaamadaha maareynta miisaanka.

Waxaa xusid mudan in, oo ay la socdaan Novo Nordisk loo yaqaan "GLP-1 duo" LLY ayaa sidoo kale kor u qaadaysa liiska GLP-1 miisaan lumis daroogada Tirzepatide ee Shiinaha, kaas oo sidoo kale la filayo in la ansixiyo gudaha.2023 August, LLY Shiinaha ayaa ku dhawaaqay in, sida laga soo xigtay website-ka rasmiga ah ee Xarunta Qiimaynta Dawooyinka ee Maamulka Dawooyinka ee Gobolka.Codsiga diiwaangelinta ee duritaanka Tirzepatide ee hagaajinta maaraynta miisaanka muddada-dheer ee bukaannada cayilan ee leh cayilka qaangaarka ah ama leh ugu yaraan hal miisaan oo la xiriira miisaanka oo ku saleysan cunto kaloriin yar iyo jimicsi kordhay ayaa si rasmi ah loo aqbalay.

Tilmaamaha cudurka macaanka ee Tirzepatide waxaa lagu ansixiyay Mareykanka bishii Maajo 2022, daawaduna waxay ku biirisay $483 milyan dakhli Lilly sanadka 2022. Tilmaanta miisaan dhimista ee Tirzepatide waxaa Mareykanka loogu oggolaaday miisaan lumis November 8, 2023, ka dib wax ka yar laba bilood oo dakhli ka yar $176 milyan.

Iyada oo daawooyinka Novo Nordisk iyo LLY GLP-1 la filayo in loo oggolaado calaamadaha miisaan lumis ee Shiinaha, tartanka u dhexeeya Novo Nordisk iyo LLY ee wadada GLP-1 ayaa laga yaabaa inay dhawaan ka bilaabmaan Shiinaha.